Findings from the CoronavRheum trial suggest that suspension of methotrexate for 2 weeks after each dose of the Sinovac inactivated SARS-CoV-2 vaccine may improve antibody response rates to vaccination among people with rheumatoid arthritis.
Study findings suggest that mRNA vaccines against SARS-CoV-2 have good short-term safety and immunogenicity profiles in adolescents with juvenile-onset rheumatic diseases.
With rituximab-treated patients having an elevated risk for severe COVID-19 and a reduced likelihood of responding to vaccines, Sebastian Sattui and David Jayne discuss how these challenges can be addressed and explore the future role of the drug for the treatment of rheumatic diseases.
